SkinBioTherapeutics PLC (LSE:SBTX) — Market Cap & Net Worth
Market Cap & Net Worth: SkinBioTherapeutics PLC (SBTX)
SkinBioTherapeutics PLC (LSE:SBTX) has a market capitalization of $307.45K (GBX2.53 Billion) as of June 20, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30996 globally and #977 in its home market, demonstrating a 24.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SkinBioTherapeutics PLC's stock price GBX9.75 by its total outstanding shares 259168671 (259.17 Million). Review how much debt does SkinBioTherapeutics PLC carry to assess the company's total debt and financial obligations.
SkinBioTherapeutics PLC Market Cap History: 2017 to 2026
SkinBioTherapeutics PLC's market capitalization history from 2017 to 2026. Data shows change from $287.74K to $307.45K (-3.35% CAGR).
Index Memberships
SkinBioTherapeutics PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.03% | #264 of 722 |
Weight: SkinBioTherapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SkinBioTherapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SkinBioTherapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
SkinBioTherapeutics PLC's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $488.77K | $74.76K | -$2.79 Million | 6.54x | N/A |
| 2023 | $480.88K | $132.06K | -$2.84 Million | 3.64x | N/A |
| 2024 | $583.37K | $1.21 Million | -$2.88 Million | 0.48x | N/A |
| 2025 | $496.65K | $4.64 Million | -$696.25K | 0.11x | N/A |
Competitor Companies of SBTX by Market Capitalization
Companies near SkinBioTherapeutics PLC in the global market cap rankings as of June 20, 2026.
Key companies related to SkinBioTherapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
SkinBioTherapeutics PLC Historical Marketcap From 2017 to 2026
Between 2017 and today, SkinBioTherapeutics PLC's market cap moved from $287.74K to $ 307.45K, with a yearly change of -3.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX307.45K | -38.10% |
| 2025 | GBX496.65K | -14.86% |
| 2024 | GBX583.37K | +21.31% |
| 2023 | GBX480.88K | -1.61% |
| 2022 | GBX488.77K | -63.10% |
| 2021 | GBX1.32 Million | +78.72% |
| 2020 | GBX741.03K | +62.07% |
| 2019 | GBX457.23K | +7.41% |
| 2018 | GBX425.70K | +47.95% |
| 2017 | GBX287.74K | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of SkinBioTherapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $307.45K USD |
| MoneyControl | $307.45K USD |
| MarketWatch | $307.45K USD |
| marketcap.company | $307.45K USD |
| Reuters | $307.45K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more